Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Lark

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Pharmacology|May 22, 2002
Novel bone antiresorptive approachesMichael W Lark, Ian E James
Trends in Pharmacological Sciences|June 1, 2014
Biased ligands at G-protein-coupled receptors: promise and progressJonathan D Violin, Aimee L Crombie, David G Soergel, et al.
Trends in Cardiovascular Medicine|March 19, 2013
GPCR biased ligands as novel heart failure therapeuticsJonathan D Violin, David G Soergel, Guido Boerrigter, et al.
Circulation. Heart Failure|August 15, 2012
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failureGuido Boerrigter, David G Soergel, Jonathan D Violin, et al.
Journal of Clinical Pharmacology|July 2, 2013
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteersDavid G Soergel, Ruth Ann Subach, Conrad L Cowan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonistSandra J Hoffman, Janice Vasko-Moser, William H Miller, et al.
Circulation. Heart Failure|August 13, 2011
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failureGuido Boerrigter, Michael W Lark, Erin J Whalen, et al.
Journal of Clinical Pharmacology|October 15, 2013
First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteersDavid G Soergel, Ruth Ann Subach, Brian Sadler, et al.
Arthritis and Rheumatism|March 17, 2004
Mechanisms and kinetics of glycosaminoglycan release following in vitro cartilage injuryMichael A DiMicco, Parth Patwari, Patrick N Siparsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 31, 2010
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performanceJonathan D Violin, Scott M DeWire, Dennis Yamashita, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|May 22, 2002
Novel bone antiresorptive approachesMichael W Lark, Ian E James
Trends in Pharmacological Sciences|June 1, 2014
Biased ligands at G-protein-coupled receptors: promise and progressJonathan D Violin, Aimee L Crombie, David G Soergel, et al.
Trends in Cardiovascular Medicine|March 19, 2013
GPCR biased ligands as novel heart failure therapeuticsJonathan D Violin, David G Soergel, Guido Boerrigter, et al.
Circulation. Heart Failure|August 15, 2012
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failureGuido Boerrigter, David G Soergel, Jonathan D Violin, et al.
Journal of Clinical Pharmacology|July 2, 2013
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteersDavid G Soergel, Ruth Ann Subach, Conrad L Cowan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonistSandra J Hoffman, Janice Vasko-Moser, William H Miller, et al.
Circulation. Heart Failure|August 13, 2011
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failureGuido Boerrigter, Michael W Lark, Erin J Whalen, et al.
Journal of Clinical Pharmacology|October 15, 2013
First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteersDavid G Soergel, Ruth Ann Subach, Brian Sadler, et al.
Arthritis and Rheumatism|March 17, 2004
Mechanisms and kinetics of glycosaminoglycan release following in vitro cartilage injuryMichael A DiMicco, Parth Patwari, Patrick N Siparsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 31, 2010
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performanceJonathan D Violin, Scott M DeWire, Dennis Yamashita, et al.
Pageof 2